Device JCAs Launch, NICE Prioritisation, and MFN Reality Check

Episode 16 — 30 May 2026 Medical device JCAs launch in June as NICE implements new prioritisation framework. Trump's MFN commitments clash with reality as pharma raises prices on over 350 products. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Transcript

SPEAKER_01 0:00

Welcome to Access Brief, the daily AI podcast on Qi or HTA and Market Access. I'm Marcus with Sarah. Today, medical device JCA is launching in June, NICE's new prioritization board in action, and the growing disconnect between MFN commitments and actual pricing behavior. Let's get into it.

SPEAKER_00 0:17

The HTAXG is planning to initiate approximately five medical device JCAs starting in June 2026. This marks the next phase beyond cancer medicines and ATMPs that launched in January 2025.

SPEAKER_01 0:30

The methodological challenges here are substantial. The medical device JCA framework represents a complex challenge given the heterogeneity of devices compared to pharmaceuticals. We're talking about fundamentally different evidence generation paradigms.

SPEAKER_00 0:44

Exactly, but I think we're underestimating the commercial implications. Device manufacturers have been operating in fragmented national HTA systems for decades. A unified EU approach could actually streamline their evidence strategies, even if the initial methodology is imperfect.

SPEAKER_01 1:00

I'm not convinced. The heterogeneity isn't just about evidence types, it's about fundamental differences in how devices evolve post-market. The traditional JCA model assumes static interventions. Devices iterate continuously. How do you assess something that's changing?

SPEAKER_00 1:16

Fair point, but that's exactly why this is worth watching. The HTAC will need to develop adaptive assessment frameworks. If they crack this, it could influence how we think about other evolving technologies.

SPEAKER_01 1:27

Or it could create a bureaucratic nightmare that stifles innovation. Five assessments isn't enough to stress test the methodology, but it's enough to create precedents that might be hard to unwind.

SPEAKER_00 1:39

NICE's new prioritization board met for the first time on the 29th of May, establishing a unified framework for topic selection that replaces previously fragmented processes. The board's first decisions focus on addressing unmet clinical need and workforce constraints.

SPEAKER_01 1:54

Priority areas include digital therapeutics for mental health conditions. This suggests NICE is finally taking a strategic approach to guidance development rather than just responding to manufacturer submissions.

SPEAKER_00 2:06

I'm skeptical about the execution. Prioritization sounds rational, but it fundamentally shifts power dynamics. Manufacturers lose some control over timing, and that could affect commercial strategies significantly.

SPEAKER_01 2:18

That's the point, isn't it? NICE has limited resources. If they're constantly reacting to industry timelines, they can't focus on areas where guidance would have the most clinical impact.

SPEAKER_00 2:29

But who defines impact? Digital therapeutics for mental health might tick policy boxes, but if the evidence base isn't robust enough to support meaningful recommendations, you're just creating guidance for guidance's sake.

SPEAKER_01 2:41

The workforce constraints angle is interesting, though. NICE is acknowledging their own capacity limitations openly. That's refreshingly honest and suggests the prioritization framework might actually be about operational reality rather than just policy theater.

SPEAKER_00 2:56

True, but it also raises questions about whether NICE has the right capacity in the right areas. Prioritizing topics doesn't solve fundamental expertise gaps.

SPEAKER_01 3:04

The MHRA NICE Aligned Pathway launched April 1st is showing early implementation challenges despite promises of three, six-month faster patient access. Meanwhile, we're seeing a significant disconnect between MFN commitments and actual pricing behavior.

SPEAKER_00 3:19

Pharmaceutical companies are raising prices on over 350 branded products in 2026, up from 250 in 2025, despite 15 major companies signing MFN agreements. Pfizer leads with 80 product price increases, including a 15% bump to community COVID vaccine. But look at the Medicare negotiation data. Six drugs saw substantial list price cuts, averaging 40% between 2024 and 2026. The IRA is creating real pricing pressure where it has teeth.

SPEAKER_01 4:04

That's my point. Where there are actual consequences, behavior changes. MFN is voluntary theater, Medicare negotiation has statutory backing. Companies respond to real incentives, not policy wishes.

SPEAKER_00 4:17

I think you're missing the longer game. MFN might be setting expectations for future mandatory policies. Companies are testing how far they can push before facing real regulatory backlash.

SPEAKER_01 4:27

Or they're demonstrating that voluntary approaches don't work, which undermines the credibility of future negotiations. If you can't get compliance on voluntary commitments, why should anyone believe mandatory ones will be different?

SPEAKER_00 4:40

Because mandatory ones come with penalties. The MFN experiment might be gathering evidence for more aggressive interventions.

SPEAKER_01 4:47

EMA published a comprehensive review of regulator-led RWE studies, identifying 61 research opportunities with 30 studies initiated, and 27 completed between September 2021 and February 2023. They're noting challenges in timely evidence generation and recommending earlier identification of research needs.

SPEAKER_00 5:08

Recent FDA accelerated approvals in May include HEPCLUDEX for hepatitis delta virus and Bacalsey for mantle cell lymphoma, both under accelerated pathways. This highlights continued regulatory flexibility for serious conditions with limited treatment options.

SPEAKER_01 5:24

The EMA's RWE integration is methodologically sound but operationally slow. Identifying 61 opportunities but only completing 27 studies over 18 months suggests significant execution gaps.

SPEAKER_00 5:36

The FDA approvals show a different approach, accepting uncertainty for serious unmet need. There's a fundamental tension between the European desire for comprehensive evidence and the American willingness to act on incomplete data.

SPEAKER_01 5:49

Both approaches have merit, but they're creating divergent regulatory environments that complicate global development strategies.

SPEAKER_00 5:55

The MFN pricing disconnect shows policy ambitions colliding with commercial reality. Meanwhile, device JCAs and nice prioritization represent genuine structural changes that could reshape market access.

SPEAKER_01 6:08

Implementation will determine impact. Good policy design means nothing without effective execution. Back tomorrow on Access Brief. Show notes at outcomes analytica.no.